0001860657
false
0001860657
2023-12-05
2023-12-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 5, 2023
ALLARITY THERAPEUTICS, INC.
(Exact name of registrant as specified in our charter)
Delaware |
|
001-41160 |
|
87-2147982 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
24 School Street, 2nd Floor,
Boston, MA |
|
02108 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
(401) 426-4664
(Registrant’s telephone number, including
area code)
Not applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐ |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par value $0.0001 per share |
|
ALLR |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01 Regulation FD Disclosure
On
December 5, 2023, Allarity Therapeutics, Inc. (the “Company”) issued a press release regarding its Early Phase 2 Stenoparib
Clinical Data. A copy of the press release is attached as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by reference.
The
information reported under Item 7.01 in this Current Report on Form 8-K, including Exhibit 99.1, is being “furnished” and
shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)
or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing. This Current Report on
Form 8-K will not be deemed an admission as to the materiality of any information contained herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Allarity Therapeutics, Inc. |
|
|
|
By: |
/s/ James G. Cullem |
|
|
James G. Cullem
Chief Executive Officer |
|
|
|
Dated: December 5, 2023 |
|
|
Exhibit 99.1
| - | All evaluable participants, with prior PARP inhibitor therapy and chemotherapy, showed significant tumor
shrinkage including one complete response |
| - | Early data follows Phase 2 dose optimization change from once-daily to twice-daily |
Boston (December 5, 2023) — Allarity Therapeutics, Inc.
(“Allarity” or the “Company”) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology
therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced encouraging
initial results from its ongoing Phase 2 clinical trial evaluating the efficacy of its PARP inhibitor, stenoparib, in women with advanced
ovarian cancer (AOC). Of the five evaluable patients included in the initial data analysis, one patient experienced a complete response
and the other four demonstrated stable disease.
Investigators prescreened women with AOC using Allarity’s DRP®-Stenoparib CDx,
a complex transcriptomic signature comprising 414 mRNA biomarkers indicative of response/resistance to the drug. Each woman was assigned
a DRP®-score, and those with scores above 50%, which suggested a higher likelihood of benefiting from treatment with stenoparib,
were selected for treatment. Selected patients received stenoparib in a twice daily (BID) dosing regimen (200 mg morning, 400 mg evening)
under a change in protocol, implemented earlier in the year, from prior once-daily dosing of 600 mg. Allarity implemented the protocol
change to optimize the drug exposure taking into account the half-life of stenoparib in patients.
Of the 22 patients screened with the DRP®-Stenoparib CDx,
17 DRP® positive patients were identified. Eleven women have entered treatment, and among the five evaluable participants
assessed up to the data evaluation cut-off, there were early signs of clinical benefit in all cases:
| · | One patient experienced a complete response (CR) by scan (to be confirmed
by second scan) and by decreased levels of CA125 (a biomarker of AOC). |
| · | One patient experienced stable disease with tumor shrinkage of 19%. |
| · | One patient experienced stable disease for more than 24 weeks with tumor
shrinkage of 11%. |
| · | Two patients experienced stable disease with tumor shrinkage of 8%. |
Allarity
Therapeutics, Inc. I 24 School Street, 2nd Floor I Boston, MA I U.S.A.
I NASDAQ: ALLR I www.allarity.com
All five patients had previously been treated with another PARP inhibitor.
All five patients remain in treatment with stenoparib and the four that did not have complete responses are showing stable disease at
this time.
“We are enthusiastic about these early, promising
data since the observed clinical benefit indicates that stenoparib is active in ovarian
cancer patients selected with the DRP® -Stenoparib CDx, even though these women had prior PARP inhibitor
therapy and chemotherapy. While still early, these data suggest that BID dosing of this drug, and the use of the DRP® -Stenoparib CDx
for patient selection and treatment, may provide advanced ovarian cancer patients meaningful benefit. The DRP® -Stenoparib
CDx, if approved, may provide clinicians with an important diagnostic to guide patient treatment in
this hard-to-treat patient population," said Marie Foegh, M.D., Chief Medical Officer of Allarity.
The initial data readout is from an ongoing Phase 2 open-label, single-arm
trial that Allarity is conducting at multiple sites in the U.S. and Europe. The goal of the study is to evaluate the anti-tumor effect
of stenoparib as monotherapy in DRP®-selected patients with locally recurrent or metastatic ovarian cancer
after previous PARP inhibitor and chemotherapy treatments. The primary endpoint is objective response rate (ORR). Allarity anticipates
an interim data readout in Q1 2024.
The DRP®-Stenoparib CDx is a transcriptomic signature
comprising 414 mRNA biomarkers that are collectively predictive of tumor sensitivity or resistance to stenoparib. Using the DRP® CDx
to select likely responder patients while excluding likely resistant ones, Allarity aims to improve the benefit-risk ratio of stenoparib in
metastatic or locally advanced ovarian cancer. The initial data from Allarity’s ongoing DRP®-guided Phase 2 study
of stenoparib suggests that the DRP®-Stenoparib CDx may identify a subset of AOC patients previously treated
with a PARP inhibitor who may benefit from treatment with stenoparib. The DRP®-Stenoparib CDx is a clinical-stage
companion diagnostic candidate and has not yet been approved by the U.S. FDA or the EU’s EMA.
All preliminary data are subject to change until the final study data
readout. Early trial results may not be a reliable indicator of subsequent trial results based on a larger patient population.
About Stenoparib
Stenoparib is an orally-available, small molecule dual-targeted inhibitor
of PARP1/2 and telomerase maintenance enzymes (Tankyrase 1 and 2). At present, tankyrases are attracting significant attention as emerging
therapeutic targets for cancer, principally due to their role in the Wnt signaling pathway. Aberrant Wnt/β-catenin
signaling has been implicated in the development and progression of multiple cancers, potentially giving stenoparib a unique, dual tumor
inhibitory action. Stenoparib was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121. Allarity
has the exclusive, global rights for the development and commercialization of stenoparib.
Allarity
Therapeutics, Inc. I 24 School Street, 2nd Floor I Boston, MA I U.S.A.
I NASDAQ: ALLR I www.allarity.com
Page 2 of 4
Some approved PARP inhibitors have recently been shown to be associated
with less favorable survival outcomes than initially established. Allarity’s Phase 2 trial data for stenoparib to date shows that
the drug has much less myelotoxicity than the FDA approved PARP inhibitors. Specifically, in 42 evaluable women in Phase 2 studies with
stenoparib, anemia (21%), neutropenia (2%) and thrombocytopenia (0%) was lower than the approved PARP inhibitor niraparib with anemia
51%, neutropenia in 20% and thrombocytopenia oberved in in 52% of 463 patients. Allarity anticipates that this lower myelotoxicity may
make stenoparib a better candidate for combination with other drugs. Allarity is studying the therapeutic potential of stenoparib in combination
with dovitinib (a pan-targeted kinase inhibitor) in an ongoing Phase 1b trial, with an anticipated data readout near early Q2 2024. The
Company believes that stenoparib may have broad therapeutic potential in combination with other anti-tumor agents.
About Allarity Therapeutics
Allarity Therapeutics, Inc. (Nasdaq: ALLR)
develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the
DRP® platform. The Company has a mature portfolio of three drug candidates: stenoparib, a PARP inhibitor in Phase
2 development for ovarian cancer, and in Phase 1 development for advanced solid tumors in a combination treatment with dovitinib, a pan-tyrosine
kinase inhibitor (pan-TKI) that has previously been developed through Phase 3 in renal cancer; and IXEMPRA® (Ixabepilone),
a microtubule inhibitor approved in the U.S. and marketed by R-PHARM U.S. for the treatment of second-line metastatic breast cancer, currently
in Phase 2 development in Europe for the same indication. Additionally, the Company has rights in two secondary assets: 2X-111, a liposomal
formulation of doxorubicin for metastatic breast cancer and/or glioblastoma multiforme (GBM), which is the subject of discussions for
a restructured out-license to Smerud Medical Research International AS; and LiPlaCis®, a liposomal formulation of cisplatin
and its accompanying DRP®, being developed via a partnership with CHOSA Oncology AB for late-stage metastatic breast cancer.
The Company is headquartered in the United States and maintains an R&D facility in Hoersholm, Denmark. For more information, please
visit the Company’s website at www.Allarity.com.
About the Drug Response Predictor – DRP® Companion
Diagnostic
Allarity uses its drug-specific DRP®
to select those patients who, by the genetic signature of their cancer, are found to have a high likelihood of responding to the specific
drug. By screening patients before treatment, and only treating those patients with a sufficiently high DRP® score,
the therapeutic response rate can be significantly increased. The DRP® method builds on the comparison of sensitive
vs. resistant human cancer cell lines, including transcriptomic information from cell lines combined with clinical tumor biology filters
and prior clinical trial outcomes. DRP® is based on messenger RNA from patient biopsies. The DRP®
platform has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer
patients in 37 out of 47 clinical studies that were examined (both retrospective and prospective), including ongoing, prospective Phase
2 trials of Stenoparib and IXEMPRA®. The DRP® platform, which can be used in all cancer types and
is patented for more than 70 anti-cancer drugs, has been extensively published in peer-reviewed literature.
Follow Allarity on Social Media
LinkedIn: https://www.linkedin.com/company/allaritytx/
Twitter: https://twitter.com/allaritytx
Allarity
Therapeutics, Inc. I 24 School Street, 2nd Floor I Boston, MA I U.S.A.
I NASDAQ: ALLR I www.allarity.com
Page 3 of 4
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide Allarity’s
current expectations or forecasts of future events. The words “anticipates,” “believe,” “continue,”
“could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,”
“possible,” “potential,” “predicts,” “project,” “should,” “would”
and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not
forward-looking. These forward-looking statements include, but are not limited to, statements related to the expected availability of
capital to fund its anticipated clinical trials, statements related to advancing dovitinib in combination with stenoparib or another therapeutic
candidate or other approved drug, any statements related to ongoing clinical trials for stenoparib as a monotherapy or in combination
with another therapeutic candidate for the treatment of advanced ovarian cancer, or ongoing clinical trials (in Europe) for IXEMPRA® for
the treatment of metastatic breast cancer, statements relating to the effectiveness of the Company’s DRP® companion
diagnostics platform in predicting whether a particular patient is likely to respond to a specific drug, and statements related to the
Company’s ability to regain compliance with the Nasdaq Listing Rule. Any forward-looking statements in this press release are based
on management’s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties
include, but are not limited to, the risk that the Company is not able to raise sufficient capital to support its current and anticipated
clinical trials, the risk that early results of a clinical study do not necessarily predict final results and that one or more of
the clinical outcomes may materially change following more comprehensive reviews of the data, and as more patient data become available,
the risk that results of a clinical study are subject to interpretation and additional analyses may be needed and/or may contradict such
results, the receipt of regulatory approval for stenoparib, dovitinib or any of our other therapeutic candidates and companion diagnostics
or, if approved, the successful commercialization of such products, the risk of cessation or delay of any of the ongoing or planned clinical
trials and/or our development of our product candidates, the risk that the results of previously conducted studies will not be repeated
or observed in ongoing or future studies involving our therapeutic candidates, and the risk that the current COVID-19 pandemic will impact
the Company’s current and future clinical trials and the timing of the Company’s preclinical studies and other operations.
For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ
from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our Form S-1 registration
statement filed on October 30, 2023, as amended and our Form 10-K annual report on file with the Securities and Exchange Commission,
available at the Securities and Exchange Commission’s website at www.sec.gov ,
and as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with
the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes
no duty to update this information unless required by law.
###
Company Contact:
investorrelations@allarity.com
U.S. Media Contact:
Mike Beyer
Sam Brown, Inc.
+1 (312) 961-2502
mikebeyer@sambrown.com
EU Media Contact:
Thomas Pedersen
Carrotize PR & Communications
+45 6062 9390
tsp@carrotize.com
Allarity
Therapeutics, Inc. I 24 School Street, 2nd Floor I Boston, MA I U.S.A.
I NASDAQ: ALLR I www.allarity.com
Page 4 of 4
v3.23.3
Cover
|
Dec. 05, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Dec. 05, 2023
|
Entity File Number |
001-41160
|
Entity Registrant Name |
ALLARITY THERAPEUTICS, INC.
|
Entity Central Index Key |
0001860657
|
Entity Tax Identification Number |
87-2147982
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
24 School Street
|
Entity Address, Address Line Two |
2nd Floor
|
Entity Address, City or Town |
Boston
|
Entity Address, State or Province |
MA
|
Entity Address, Postal Zip Code |
02108
|
City Area Code |
(401)
|
Local Phone Number |
426-4664
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, par value $0.0001 per share
|
Trading Symbol |
ALLR
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Allarity Therapeutics (NASDAQ:ALLR)
Historical Stock Chart
From Apr 2024 to May 2024
Allarity Therapeutics (NASDAQ:ALLR)
Historical Stock Chart
From May 2023 to May 2024